Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2025-02-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于子公司获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary receiving approval from the National Medical Products Administration for a chemical raw material drug listing application. It includes details about the drug, approval number, validity, and risk warnings. The document is short (814 characters) and serves as a formal notification of regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-20 Chinese
第四届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the seventh meeting of the fourth board of directors of Sailong Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. It does not contain financial statements or detailed management discussion but focuses on board decisions and governance matters. The document also references other announcements for specific matters but itself is a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or financial statement, so it is not an Annual Report or Interim Report. Confidence is high due to clear identification of board meeting resolutions and voting results.
2025-02-13 Chinese
第四届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 赛隆药业集团股份有限公司 regarding a meeting held on February 13, 2025. It details the meeting's convening, attendance, and the approval of a proposal related to applying for bank credit with guarantees from the actual controller. It includes voting results and references another announcement for more details. The document is short (765 characters) and serves as an official announcement of a board meeting decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-02-13 Chinese
《舆情管理制度》
Governance Information Classification · 95% confidence The document is titled as a "舆情管理制度" which translates to "Public Opinion Management System" or "Crisis Management Policy" for the company. It outlines internal policies, responsibilities, and procedures for managing public opinion and media crises, including communication with regulatory bodies like the Guangdong Securities Regulatory Bureau and Shenzhen Stock Exchange. It does not contain financial data, earnings, audit information, or any report of financial performance. It is a governance-related internal policy document approved by the board. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-02-13 Chinese
第四届董事会独立董事2025年第一次专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the independent directors of the board regarding a specific agenda item about bank credit application and guarantees. It references company law, securities law, stock exchange listing rules, and internal governance guidelines. The content focuses on board-level review and approval of related party transactions and conflicts of interest, with signatures of independent directors. There is no financial data, earnings information, or report publication mentioned. The document is clearly related to board/management information, specifically the independent directors' review and opinion on a board matter. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a substantive board opinion.
2025-02-13 Chinese
关于公司向银行申请授信并由实际控制人提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding its application for bank credit facilities and guarantees provided by its actual controllers. It details the credit amounts, terms, related party information, financial data, decision-making procedures, and approvals by the board and supervisory committee. The document is a formal disclosure of a financing-related transaction but does not contain comprehensive financial statements or detailed financial performance analysis. It is not an earnings release or an annual/interim report. The focus is on the update about capital raising activities and guarantees, which fits the category of Capital/Financing Update (CAP). The document length is about 3000 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2025-02-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.